{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:51:23Z","timestamp":1770987083397,"version":"3.50.1"},"reference-count":38,"publisher":"American Society of Consultant Pharmacists","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Consultant Pharmacist"],"published-print":{"date-parts":[[2013,3,1]]},"DOI":"10.4140\/tcp.n.2013.176","type":"journal-article","created":{"date-parts":[[2013,3,6]],"date-time":"2013-03-06T03:03:30Z","timestamp":1362539010000},"page":"176-183","source":"Crossref","is-referenced-by-count":23,"title":["Colchicine-Antimicrobial Drug Interactions: What Pharmacists Need to Know in Treating Gout"],"prefix":"10.4140","volume":"28","author":[{"given":"Matthew W.","family":"Davis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suman","family":"Wason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer L.","family":"DiGiacinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","published-online":{"date-parts":[[2013,3,5]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0889-857X(21)00975-3","article-title":"Therapy in gout","volume":"14","author":"SL Wallace","year":"1988","journal-title":"Rheum Dis Clin North Am"},{"key":"2","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"GC Borstad","year":"2004","journal-title":"J Rheumatol"},{"issue":"6 Suppl 1","key":"3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3810\/pgm.2011.11.2511","article-title":"recommendations for the diagnosis and management of gout and hyperuricemia","volume":"123","author":"M Hamburger","year":"2011","journal-title":"Postgrad Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","article-title":"Prevalence of contraindications and prescription of pharmacologic therapies for gout","volume":"124","author":"RT Keenan","year":"2011","journal-title":"Am J Med"},{"key":"5","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout","volume":"46","author":"KM Jordan","year":"2007","journal-title":"Rheumatology"},{"key":"6","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.2165\/11205470-000000000-00000","article-title":"Oral colchicine (Colcrys): in the treatment and prophylaxis of gout","volume":"70","author":"LP Yang","year":"2010","journal-title":"Drugs"},{"key":"7","unstructured":"Colcrys (colchicine, USP) tablets for oral use: prescribing information. March 14, 2012. Available at http:\/\/www.colcrys.com\/assets\/pdf\/COLCRYS_Full_Prescribing_Information.pdf. Accessed June 12, 2012. <a target=\"_blank\" href='http:\/\/www.colcrys.com\/assets\/pdf\/COLCRYS_Full_Prescribing_Information.pdf'>http:\/\/www.colcrys.com\/assets\/pdf\/COLCRYS_Full_Prescribing_Information.pdf<\/a>"},{"key":"8","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1185\/03007995.2010.533647","article-title":"Chronic gout: epidemiology, disease progression, treatment and disease burden","volume":"26","author":"RA Brook","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","article-title":"Pathogenesis of gout","volume":"143","author":"HK Choi","year":"2005","journal-title":"Ann Intern Med"},{"key":"10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/ncprheum0556","article-title":"The changing epidemiology of gout","volume":"3","author":"E Roddy","year":"2007","journal-title":"Natl Clin Pract Rheumatol"},{"key":"11","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008","volume":"63","author":"Y Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"12","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1185\/03007995.2011.563284","article-title":"A new perspective on the pharmacoeconomics of colchicine","volume":"27","author":"AI Wertheimer","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"13","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/ar3199","article-title":"Epidemiology of gout","volume":"12","author":"E Roddy","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"14","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare","volume":"62","author":"RA Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"key":"15","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.clinthera.2011.01.008","article-title":"Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials","volume":"32","author":"RL Wortmann","year":"2010","journal-title":"Clin Ther"},{"key":"16","first-page":"20","article-title":"Gout in the elderly","volume":"19","author":"TC Ning","year":"2010","journal-title":"Clin Geriatr"},{"key":"17","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s12325-012-0028-6","article-title":"Are dosing adjustments required for colchicine in the elderly compared with younger patients?","volume":"29","author":"S Wason","year":"2012","journal-title":"Adv Ther"},{"key":"18","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jbspin.2006.03.006","article-title":"Colchicine today","volume":"73","author":"E Niel","year":"2006","journal-title":"Joint Bone Spine"},{"key":"19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.semarthrit.2008.08.006","article-title":"Colchicine update: 2008","volume":"38","author":"RA Terkeltaub","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"F Martinon","year":"2006","journal-title":"Nature"},{"key":"21","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/j.1552-4604.1996.tb04753.x","article-title":"Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses","volume":"36","author":"GM Ferron","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"22","first-page":"1334","article-title":"Colchicine use in cyclosporine treated transplant recipients: how little is too much?","volume":"27","author":"PA Simkin","year":"2000","journal-title":"J Rheumatol"},{"key":"23","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1124\/dmd.109.028282","article-title":"Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine","volume":"37","author":"A Dahan","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"24","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1023\/A:1011914902121","article-title":"P-glycoprotein is more efficient at limiting uptake than inducing efflux of colchicine and vinblastine in HL-60 cells","volume":"15","author":"X Decleves","year":"1998","journal-title":"Pharm Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.taap.2006.08.004","article-title":"Is P-glycoprotein (ABCB1) a phase 0 or a phase 3 colchicine transporter depending on colchicine exposure conditions?","volume":"217","author":"X Decleves","year":"2006","journal-title":"Toxicol Appl Pharmacol"},{"key":"26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1006\/cbir.1995.1051","article-title":"Colchicineresistance and enhancement of P-glycoprotein activity after cocultivation of drug-sensitive cells with multidrug resistant variants","volume":"19","author":"AV Eliseenkova","year":"1995","journal-title":"Cell Biol Int"},{"key":"27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/138920008784220664","article-title":"Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4","volume":"9","author":"SF Zhou","year":"2008","journal-title":"Curr Drug Metab"},{"key":"28","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00003088-200847100-00004","article-title":"General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information","volume":"47","author":"Y Ohno","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"29","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1002\/art.30389","article-title":"Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A\/P-glycoprotein inhibitors","volume":"63","author":"RA Terkeltaub","year":"2011","journal-title":"Arthritis Rheum"},{"key":"30","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3109\/15563650.2010.495348","article-title":"Colchicine poisoning: the dark side of an ancient drug","volume":"48","author":"Y Finkelstein","year":"2010","journal-title":"Clin Toxicol"},{"key":"31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/431592","article-title":"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: a retrospective study","volume":"41","author":"IF Hung","year":"2005","journal-title":"Clin Infect Dis"},{"key":"32","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/01.SMJ.0000163315.02563.B2","article-title":"Two probable cases of serious drug interaction between clarithromycin and colchicine","volume":"98","author":"VC Cheng","year":"2005","journal-title":"South Med J"},{"key":"33","first-page":"515","article-title":"Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure","volume":"19","author":"I Akdag","year":"2006","journal-title":"J Nephrol"},{"key":"34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/RHU.0b013e3181bbbcd7","article-title":"Short term treatment with clarithromycin resulting in colchicine-induced rhabdomyolysis","volume":"15","author":"J McKinnell","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"35","first-page":"204","article-title":"Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin","volume":"66","author":"W van der Velden","year":"2008","journal-title":"Neth J Med"},{"key":"36","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1345\/aph.1E197","article-title":"Acute colchicine intoxication during clarithromycin administration","volume":"38","author":"F Rollot","year":"2004","journal-title":"Ann Pharmacother"},{"key":"37","first-page":"494","article-title":"Acute colchicine intoxication\u2014possible role of erythromycin administration","volume":"19","author":"Y Caraco","year":"1991","journal-title":"Rheumatol"},{"key":"38","doi-asserted-by":"crossref","first-page":"990","DOI":"10.2174\/138161208784139738","article-title":"Potential strategies for minimizing mechanisms-based inhibition of cytochrome P450 3A4","volume":"14","author":"SF Zhou","year":"2008","journal-title":"Curr Pharm Dis"}],"container-title":["The Consultant Pharmacist"],"original-title":[],"deposited":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T05:41:41Z","timestamp":1644471701000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ingentaconnect.com\/content\/ascp\/tcp\/2013\/00000028\/00000003\/art00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,1]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3,1]]}},"alternative-id":["64T1836523534260"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2013.176","relation":{},"ISSN":["0888-5109"],"issn-type":[{"value":"0888-5109","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3,1]]}}}